nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—esophageal cancer	0.573	1	CbGaD
Eprosartan—ABCC2—Carboplatin—esophageal cancer	0.107	0.306	CbGbCtD
Eprosartan—ABCC2—Cisplatin—esophageal cancer	0.0917	0.262	CbGbCtD
Eprosartan—CYP2C9—Capecitabine—esophageal cancer	0.0612	0.174	CbGbCtD
Eprosartan—ABCC2—Methotrexate—esophageal cancer	0.0595	0.17	CbGbCtD
Eprosartan—CYP2C9—Cisplatin—esophageal cancer	0.0308	0.0879	CbGbCtD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.0013	0.048	CbGpPWpGaD
Eprosartan—ABCC2—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00113	0.0415	CbGpPWpGaD
Eprosartan—Serum creatinine increased—Cisplatin—esophageal cancer	0.000998	0.0201	CcSEcCtD
Eprosartan—Furunculosis—Methotrexate—esophageal cancer	0.000792	0.016	CcSEcCtD
Eprosartan—Hypertriglyceridaemia—Capecitabine—esophageal cancer	0.000788	0.0159	CcSEcCtD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000748	0.0276	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000748	0.0276	CbGpPWpGaD
Eprosartan—Serum creatinine increased—Capecitabine—esophageal cancer	0.000735	0.0148	CcSEcCtD
Eprosartan—Blood triglycerides increased—Capecitabine—esophageal cancer	0.00069	0.0139	CcSEcCtD
Eprosartan—Furuncle—Methotrexate—esophageal cancer	0.000687	0.0138	CcSEcCtD
Eprosartan—AGTR1—Arf6 trafficking events—CTNNA1—esophageal cancer	0.000663	0.0244	CbGpPWpGaD
Eprosartan—Pain—Carboplatin—esophageal cancer	0.000638	0.0129	CcSEcCtD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.000616	0.0227	CbGpPWpGaD
Eprosartan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—esophageal cancer	0.000601	0.0221	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—NOS3—esophageal cancer	0.000591	0.0218	CbGpPWpGaD
Eprosartan—Body temperature increased—Carboplatin—esophageal cancer	0.00059	0.0119	CcSEcCtD
Eprosartan—Otitis media—Capecitabine—esophageal cancer	0.000581	0.0117	CcSEcCtD
Eprosartan—CYP2C9—CYP2E1 reactions—CYP2A6—esophageal cancer	0.000578	0.0213	CbGpPWpGaD
Eprosartan—ABCC2—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00056	0.0206	CbGpPWpGaD
Eprosartan—Rigors—Capecitabine—esophageal cancer	0.000554	0.0112	CcSEcCtD
Eprosartan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—esophageal cancer	0.000547	0.0201	CbGpPWpGaD
Eprosartan—Extrasystoles—Capecitabine—esophageal cancer	0.000538	0.0108	CcSEcCtD
Eprosartan—Polyuria—Cisplatin—esophageal cancer	0.000507	0.0102	CcSEcCtD
Eprosartan—Herpes simplex—Capecitabine—esophageal cancer	0.000491	0.00989	CcSEcCtD
Eprosartan—Bone pain—Capecitabine—esophageal cancer	0.000472	0.00951	CcSEcCtD
Eprosartan—Hyponatraemia—Cisplatin—esophageal cancer	0.000447	0.00901	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—ALDH3A1—esophageal cancer	0.000444	0.0164	CbGpPWpGaD
Eprosartan—Influenza like illness—Capecitabine—esophageal cancer	0.000439	0.00885	CcSEcCtD
Eprosartan—Urinary incontinence—Capecitabine—esophageal cancer	0.000437	0.0088	CcSEcCtD
Eprosartan—Face oedema—Cisplatin—esophageal cancer	0.00043	0.00867	CcSEcCtD
Eprosartan—Gingivitis—Methotrexate—esophageal cancer	0.000429	0.00864	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—MET—esophageal cancer	0.000424	0.0156	CbGpPWpGaD
Eprosartan—Blood creatinine increased—Cisplatin—esophageal cancer	0.000417	0.00841	CcSEcCtD
Eprosartan—Oesophagitis—Capecitabine—esophageal cancer	0.000413	0.00833	CcSEcCtD
Eprosartan—Urine output increased—Capecitabine—esophageal cancer	0.000409	0.00824	CcSEcCtD
Eprosartan—Orthostatic hypotension—Cisplatin—esophageal cancer	0.000407	0.0082	CcSEcCtD
Eprosartan—Hypokalaemia—Cisplatin—esophageal cancer	0.000405	0.00817	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000401	0.00808	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—BLVRB—esophageal cancer	0.000396	0.0146	CbGpPWpGaD
Eprosartan—Abnormal vision—Capecitabine—esophageal cancer	0.000394	0.00795	CcSEcCtD
Eprosartan—Diabetes mellitus—Capecitabine—esophageal cancer	0.000377	0.00761	CcSEcCtD
Eprosartan—Sweating increased—Cisplatin—esophageal cancer	0.000375	0.00756	CcSEcCtD
Eprosartan—Polyuria—Capecitabine—esophageal cancer	0.000374	0.00754	CcSEcCtD
Eprosartan—Swelling—Capecitabine—esophageal cancer	0.000372	0.0075	CcSEcCtD
Eprosartan—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000372	0.0137	CbGpPWpGaD
Eprosartan—Gastroenteritis—Capecitabine—esophageal cancer	0.00037	0.00746	CcSEcCtD
Eprosartan—Vascular purpura—Capecitabine—esophageal cancer	0.000367	0.0074	CcSEcCtD
Eprosartan—Herpes simplex—Methotrexate—esophageal cancer	0.000365	0.00736	CcSEcCtD
Eprosartan—CYP2C9—Xenobiotics—CYP2A6—esophageal cancer	0.000358	0.0132	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000354	0.013	CbGpPWpGaD
Eprosartan—Hot flush—Capecitabine—esophageal cancer	0.000351	0.00707	CcSEcCtD
Eprosartan—Menopausal symptoms—Capecitabine—esophageal cancer	0.000348	0.00701	CcSEcCtD
Eprosartan—Atrial fibrillation—Capecitabine—esophageal cancer	0.000346	0.00698	CcSEcCtD
Eprosartan—CYP2C9—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.000344	0.0127	CbGpPWpGaD
Eprosartan—Purpura—Capecitabine—esophageal cancer	0.000341	0.00686	CcSEcCtD
Eprosartan—ABCC2—ABC-family proteins mediated transport—ABCB1—esophageal cancer	0.000338	0.0125	CbGpPWpGaD
Eprosartan—Arthritis—Capecitabine—esophageal cancer	0.000338	0.00681	CcSEcCtD
Eprosartan—Renal failure—Cisplatin—esophageal cancer	0.000337	0.0068	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—PRDX1—esophageal cancer	0.000337	0.0124	CbGpPWpGaD
Eprosartan—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000336	0.00678	CcSEcCtD
Eprosartan—Cardiac failure—Capecitabine—esophageal cancer	0.000336	0.00678	CcSEcCtD
Eprosartan—Conjunctivitis—Cisplatin—esophageal cancer	0.000334	0.00672	CcSEcCtD
Eprosartan—Hyponatraemia—Capecitabine—esophageal cancer	0.00033	0.00664	CcSEcCtD
Eprosartan—Cystitis noninfective—Methotrexate—esophageal cancer	0.000329	0.00663	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000329	0.0121	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000329	0.0121	CbGpPWpGaD
Eprosartan—Osteoarthritis—Capecitabine—esophageal cancer	0.000328	0.00662	CcSEcCtD
Eprosartan—Cystitis—Methotrexate—esophageal cancer	0.000325	0.00655	CcSEcCtD
Eprosartan—Migraine—Capecitabine—esophageal cancer	0.000323	0.00651	CcSEcCtD
Eprosartan—Face oedema—Capecitabine—esophageal cancer	0.000317	0.00639	CcSEcCtD
Eprosartan—Bradycardia—Cisplatin—esophageal cancer	0.000314	0.00632	CcSEcCtD
Eprosartan—Ataxia—Capecitabine—esophageal cancer	0.000309	0.00622	CcSEcCtD
Eprosartan—Blood creatinine increased—Capecitabine—esophageal cancer	0.000308	0.0062	CcSEcCtD
Eprosartan—CYP2C9—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000308	0.0113	CbGpPWpGaD
Eprosartan—Bladder pain—Methotrexate—esophageal cancer	0.000304	0.00613	CcSEcCtD
Eprosartan—Urine output increased—Methotrexate—esophageal cancer	0.000304	0.00613	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—SLC39A6—esophageal cancer	0.0003	0.011	CbGpPWpGaD
Eprosartan—Orthostatic hypotension—Capecitabine—esophageal cancer	0.0003	0.00604	CcSEcCtD
Eprosartan—Hypokalaemia—Capecitabine—esophageal cancer	0.000299	0.00602	CcSEcCtD
Eprosartan—Visual impairment—Cisplatin—esophageal cancer	0.000297	0.00598	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000296	0.00596	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000293	0.0108	CbGpPWpGaD
Eprosartan—Gastritis—Capecitabine—esophageal cancer	0.000291	0.00586	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00029	0.00584	CcSEcCtD
Eprosartan—Muscular weakness—Capecitabine—esophageal cancer	0.00029	0.00584	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—ABCB1—esophageal cancer	0.000289	0.0106	CbGpPWpGaD
Eprosartan—Tinnitus—Cisplatin—esophageal cancer	0.000287	0.00579	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—ADH7—esophageal cancer	0.000286	0.0105	CbGpPWpGaD
Eprosartan—Asthma—Capecitabine—esophageal cancer	0.000284	0.00572	CcSEcCtD
Eprosartan—Diabetes mellitus—Methotrexate—esophageal cancer	0.000281	0.00566	CcSEcCtD
Eprosartan—Polyuria—Methotrexate—esophageal cancer	0.000278	0.00561	CcSEcCtD
Eprosartan—CYP2C9—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.000278	0.0102	CbGpPWpGaD
Eprosartan—Sweating increased—Capecitabine—esophageal cancer	0.000276	0.00557	CcSEcCtD
Eprosartan—Angina pectoris—Capecitabine—esophageal cancer	0.000276	0.00557	CcSEcCtD
Eprosartan—Bronchitis—Capecitabine—esophageal cancer	0.000273	0.0055	CcSEcCtD
Eprosartan—Flatulence—Cisplatin—esophageal cancer	0.000264	0.00533	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000264	0.00531	CcSEcCtD
Eprosartan—Muscle spasms—Cisplatin—esophageal cancer	0.000258	0.0052	CcSEcCtD
Eprosartan—Hyperglycaemia—Capecitabine—esophageal cancer	0.000256	0.00516	CcSEcCtD
Eprosartan—Depression—Capecitabine—esophageal cancer	0.000252	0.00508	CcSEcCtD
Eprosartan—Tremor—Cisplatin—esophageal cancer	0.000251	0.00506	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—esophageal cancer	0.000249	0.00918	CbGpPWpGaD
Eprosartan—Ill-defined disorder—Cisplatin—esophageal cancer	0.000249	0.00502	CcSEcCtD
Eprosartan—Renal failure—Capecitabine—esophageal cancer	0.000249	0.00501	CcSEcCtD
Eprosartan—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000248	0.005	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—GNG7—esophageal cancer	0.000248	0.00913	CbGpPWpGaD
Eprosartan—Conjunctivitis—Capecitabine—esophageal cancer	0.000246	0.00496	CcSEcCtD
Eprosartan—Urinary tract infection—Capecitabine—esophageal cancer	0.000246	0.00496	CcSEcCtD
Eprosartan—CYP2C9—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000246	0.00906	CbGpPWpGaD
Eprosartan—Osteoarthritis—Methotrexate—esophageal cancer	0.000244	0.00493	CcSEcCtD
Eprosartan—Malaise—Cisplatin—esophageal cancer	0.000242	0.00487	CcSEcCtD
Eprosartan—Haematuria—Capecitabine—esophageal cancer	0.000241	0.00486	CcSEcCtD
Eprosartan—Epistaxis—Capecitabine—esophageal cancer	0.000239	0.00481	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.000235	0.00867	CbGpPWpGaD
Eprosartan—Bradycardia—Capecitabine—esophageal cancer	0.000231	0.00466	CcSEcCtD
Eprosartan—Ataxia—Methotrexate—esophageal cancer	0.00023	0.00463	CcSEcCtD
Eprosartan—Myalgia—Cisplatin—esophageal cancer	0.000228	0.0046	CcSEcCtD
Eprosartan—Rhinitis—Capecitabine—esophageal cancer	0.000228	0.00459	CcSEcCtD
Eprosartan—Anxiety—Cisplatin—esophageal cancer	0.000228	0.00459	CcSEcCtD
Eprosartan—Discomfort—Cisplatin—esophageal cancer	0.000226	0.00455	CcSEcCtD
Eprosartan—Pharyngitis—Capecitabine—esophageal cancer	0.000225	0.00454	CcSEcCtD
Eprosartan—Oedema peripheral—Capecitabine—esophageal cancer	0.000224	0.00451	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.000223	0.00821	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNG7—esophageal cancer	0.000222	0.00817	CbGpPWpGaD
Eprosartan—Visual impairment—Capecitabine—esophageal cancer	0.000219	0.00441	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCL2—esophageal cancer	0.000216	0.00794	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 signaling events—EGFR—esophageal cancer	0.000215	0.00792	CbGpPWpGaD
Eprosartan—Thrombocytopenia—Cisplatin—esophageal cancer	0.000214	0.00432	CcSEcCtD
Eprosartan—Tachycardia—Cisplatin—esophageal cancer	0.000214	0.00431	CcSEcCtD
Eprosartan—Tinnitus—Capecitabine—esophageal cancer	0.000212	0.00427	CcSEcCtD
Eprosartan—Hyperhidrosis—Cisplatin—esophageal cancer	0.000212	0.00426	CcSEcCtD
Eprosartan—Asthma—Methotrexate—esophageal cancer	0.000211	0.00426	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000209	0.00769	CbGpPWpGaD
Eprosartan—Anorexia—Cisplatin—esophageal cancer	0.000209	0.00421	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000208	0.00764	CbGpPWpGaD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000206	0.00758	CbGpPWpGaD
Eprosartan—Hypotension—Cisplatin—esophageal cancer	0.000205	0.00412	CcSEcCtD
Eprosartan—Chills—Capecitabine—esophageal cancer	0.000204	0.00411	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—ANXA1—esophageal cancer	0.000203	0.00748	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—ANXA1—esophageal cancer	0.000201	0.00738	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000199	0.00402	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—esophageal cancer	0.000199	0.00734	CbGpPWpGaD
Eprosartan—Paraesthesia—Cisplatin—esophageal cancer	0.000197	0.00396	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000196	0.00396	CcSEcCtD
Eprosartan—Dyspnoea—Cisplatin—esophageal cancer	0.000195	0.00393	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—SST—esophageal cancer	0.000195	0.00718	CbGpPWpGaD
Eprosartan—Flatulence—Capecitabine—esophageal cancer	0.000195	0.00393	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—CASP8—esophageal cancer	0.000194	0.00714	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—NFE2L2—esophageal cancer	0.000193	0.00712	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—GHRL—esophageal cancer	0.000193	0.00709	CbGpPWpGaD
Eprosartan—Back pain—Capecitabine—esophageal cancer	0.000191	0.00385	CcSEcCtD
Eprosartan—Decreased appetite—Cisplatin—esophageal cancer	0.00019	0.00383	CcSEcCtD
Eprosartan—Muscle spasms—Capecitabine—esophageal cancer	0.00019	0.00383	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—GHRL—esophageal cancer	0.00019	0.007	CbGpPWpGaD
Eprosartan—Depression—Methotrexate—esophageal cancer	0.000188	0.00378	CcSEcCtD
Eprosartan—Pain—Cisplatin—esophageal cancer	0.000187	0.00377	CcSEcCtD
Eprosartan—Tremor—Capecitabine—esophageal cancer	0.000185	0.00373	CcSEcCtD
Eprosartan—Renal failure—Methotrexate—esophageal cancer	0.000185	0.00373	CcSEcCtD
Eprosartan—Ill-defined disorder—Capecitabine—esophageal cancer	0.000183	0.0037	CcSEcCtD
Eprosartan—Conjunctivitis—Methotrexate—esophageal cancer	0.000183	0.00369	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000182	0.0067	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—esophageal cancer	0.000182	0.00669	CbGpPWpGaD
Eprosartan—Feeling abnormal—Cisplatin—esophageal cancer	0.00018	0.00364	CcSEcCtD
Eprosartan—Haematuria—Methotrexate—esophageal cancer	0.00018	0.00362	CcSEcCtD
Eprosartan—Malaise—Capecitabine—esophageal cancer	0.000178	0.00359	CcSEcCtD
Eprosartan—Epistaxis—Methotrexate—esophageal cancer	0.000178	0.00358	CcSEcCtD
Eprosartan—Vertigo—Capecitabine—esophageal cancer	0.000178	0.00358	CcSEcCtD
Eprosartan—Syncope—Capecitabine—esophageal cancer	0.000177	0.00357	CcSEcCtD
Eprosartan—Palpitations—Capecitabine—esophageal cancer	0.000175	0.00352	CcSEcCtD
Eprosartan—Loss of consciousness—Capecitabine—esophageal cancer	0.000174	0.0035	CcSEcCtD
Eprosartan—Body temperature increased—Cisplatin—esophageal cancer	0.000173	0.00349	CcSEcCtD
Eprosartan—Cough—Capecitabine—esophageal cancer	0.000173	0.00348	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—esophageal cancer	0.000172	0.00634	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000169	0.00623	CbGpPWpGaD
Eprosartan—Chest pain—Capecitabine—esophageal cancer	0.000168	0.00339	CcSEcCtD
Eprosartan—Myalgia—Capecitabine—esophageal cancer	0.000168	0.00339	CcSEcCtD
Eprosartan—Arthralgia—Capecitabine—esophageal cancer	0.000168	0.00339	CcSEcCtD
Eprosartan—Pharyngitis—Methotrexate—esophageal cancer	0.000168	0.00338	CcSEcCtD
Eprosartan—Anxiety—Capecitabine—esophageal cancer	0.000168	0.00338	CcSEcCtD
Eprosartan—Discomfort—Capecitabine—esophageal cancer	0.000166	0.00335	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—CYP2A6—esophageal cancer	0.000166	0.00612	CbGpPWpGaD
Eprosartan—Dry mouth—Capecitabine—esophageal cancer	0.000165	0.00332	CcSEcCtD
Eprosartan—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000163	0.00601	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000163	0.00601	CbGpPWpGaD
Eprosartan—Visual impairment—Methotrexate—esophageal cancer	0.000163	0.00328	CcSEcCtD
Eprosartan—Hypersensitivity—Cisplatin—esophageal cancer	0.000161	0.00325	CcSEcCtD
Eprosartan—Shock—Capecitabine—esophageal cancer	0.000159	0.0032	CcSEcCtD
Eprosartan—Thrombocytopenia—Capecitabine—esophageal cancer	0.000158	0.00318	CcSEcCtD
Eprosartan—Tinnitus—Methotrexate—esophageal cancer	0.000158	0.00318	CcSEcCtD
Eprosartan—Tachycardia—Capecitabine—esophageal cancer	0.000158	0.00317	CcSEcCtD
Eprosartan—Asthenia—Cisplatin—esophageal cancer	0.000157	0.00317	CcSEcCtD
Eprosartan—Hyperhidrosis—Capecitabine—esophageal cancer	0.000156	0.00314	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000155	0.00573	CbGpPWpGaD
Eprosartan—Anorexia—Capecitabine—esophageal cancer	0.000154	0.0031	CcSEcCtD
Eprosartan—Chills—Methotrexate—esophageal cancer	0.000152	0.00306	CcSEcCtD
Eprosartan—Hypotension—Capecitabine—esophageal cancer	0.000151	0.00304	CcSEcCtD
Eprosartan—Diarrhoea—Cisplatin—esophageal cancer	0.00015	0.00302	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000149	0.00548	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000147	0.00296	CcSEcCtD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000147	0.0054	CbGpPWpGaD
Eprosartan—Insomnia—Capecitabine—esophageal cancer	0.000146	0.00294	CcSEcCtD
Eprosartan—Paraesthesia—Capecitabine—esophageal cancer	0.000145	0.00292	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000145	0.00533	CbGpPWpGaD
Eprosartan—Dyspnoea—Capecitabine—esophageal cancer	0.000144	0.0029	CcSEcCtD
Eprosartan—Back pain—Methotrexate—esophageal cancer	0.000142	0.00287	CcSEcCtD
Eprosartan—Dyspepsia—Capecitabine—esophageal cancer	0.000142	0.00286	CcSEcCtD
Eprosartan—Decreased appetite—Capecitabine—esophageal cancer	0.00014	0.00283	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—esophageal cancer	0.00014	0.00517	CbGpPWpGaD
Eprosartan—Vomiting—Cisplatin—esophageal cancer	0.000139	0.0028	CcSEcCtD
Eprosartan—Fatigue—Capecitabine—esophageal cancer	0.000139	0.0028	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000139	0.00511	CbGpPWpGaD
Eprosartan—Rash—Cisplatin—esophageal cancer	0.000138	0.00278	CcSEcCtD
Eprosartan—Pain—Capecitabine—esophageal cancer	0.000138	0.00278	CcSEcCtD
Eprosartan—Constipation—Capecitabine—esophageal cancer	0.000138	0.00278	CcSEcCtD
Eprosartan—Dermatitis—Cisplatin—esophageal cancer	0.000138	0.00278	CcSEcCtD
Eprosartan—Ill-defined disorder—Methotrexate—esophageal cancer	0.000137	0.00275	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000134	0.00495	CbGpPWpGaD
Eprosartan—Feeling abnormal—Capecitabine—esophageal cancer	0.000133	0.00268	CcSEcCtD
Eprosartan—Malaise—Methotrexate—esophageal cancer	0.000133	0.00267	CcSEcCtD
Eprosartan—Vertigo—Methotrexate—esophageal cancer	0.000132	0.00266	CcSEcCtD
Eprosartan—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000132	0.00266	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000131	0.00482	CbGpPWpGaD
Eprosartan—Nausea—Cisplatin—esophageal cancer	0.00013	0.00262	CcSEcCtD
Eprosartan—Cough—Methotrexate—esophageal cancer	0.000128	0.00259	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000128	0.00472	CbGpPWpGaD
Eprosartan—Urticaria—Capecitabine—esophageal cancer	0.000128	0.00258	CcSEcCtD
Eprosartan—Abdominal pain—Capecitabine—esophageal cancer	0.000128	0.00257	CcSEcCtD
Eprosartan—Body temperature increased—Capecitabine—esophageal cancer	0.000128	0.00257	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000128	0.0047	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000126	0.00464	CbGpPWpGaD
Eprosartan—Myalgia—Methotrexate—esophageal cancer	0.000125	0.00253	CcSEcCtD
Eprosartan—Chest pain—Methotrexate—esophageal cancer	0.000125	0.00253	CcSEcCtD
Eprosartan—Arthralgia—Methotrexate—esophageal cancer	0.000125	0.00253	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—GNG7—esophageal cancer	0.000125	0.00461	CbGpPWpGaD
Eprosartan—Discomfort—Methotrexate—esophageal cancer	0.000124	0.0025	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000121	0.00444	CbGpPWpGaD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00012	0.00441	CbGpPWpGaD
Eprosartan—Hypersensitivity—Capecitabine—esophageal cancer	0.000119	0.0024	CcSEcCtD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000118	0.00436	CbGpPWpGaD
Eprosartan—Thrombocytopenia—Methotrexate—esophageal cancer	0.000118	0.00237	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—TGFBR2—esophageal cancer	0.000117	0.00429	CbGpPWpGaD
Eprosartan—Hyperhidrosis—Methotrexate—esophageal cancer	0.000116	0.00234	CcSEcCtD
Eprosartan—Asthenia—Capecitabine—esophageal cancer	0.000116	0.00233	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—HMOX1—esophageal cancer	0.000115	0.00423	CbGpPWpGaD
Eprosartan—Anorexia—Methotrexate—esophageal cancer	0.000115	0.00231	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000114	0.00422	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000114	0.00421	CbGpPWpGaD
Eprosartan—Pruritus—Capecitabine—esophageal cancer	0.000114	0.0023	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000113	0.00415	CbGpPWpGaD
Eprosartan—Hypotension—Methotrexate—esophageal cancer	0.000112	0.00226	CcSEcCtD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000111	0.0041	CbGpPWpGaD
Eprosartan—Diarrhoea—Capecitabine—esophageal cancer	0.00011	0.00222	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—ADH7—esophageal cancer	0.00011	0.00406	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CXCL2—esophageal cancer	0.00011	0.00406	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000109	0.00221	CcSEcCtD
Eprosartan—Insomnia—Methotrexate—esophageal cancer	0.000109	0.00219	CcSEcCtD
Eprosartan—Paraesthesia—Methotrexate—esophageal cancer	0.000108	0.00217	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000108	0.00397	CbGpPWpGaD
Eprosartan—Dyspnoea—Methotrexate—esophageal cancer	0.000107	0.00216	CcSEcCtD
Eprosartan—Somnolence—Methotrexate—esophageal cancer	0.000107	0.00215	CcSEcCtD
Eprosartan—Dizziness—Capecitabine—esophageal cancer	0.000107	0.00215	CcSEcCtD
Eprosartan—Dyspepsia—Methotrexate—esophageal cancer	0.000106	0.00213	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—GDI2—esophageal cancer	0.000105	0.00386	CbGpPWpGaD
Eprosartan—Decreased appetite—Methotrexate—esophageal cancer	0.000104	0.0021	CcSEcCtD
Eprosartan—Fatigue—Methotrexate—esophageal cancer	0.000104	0.00209	CcSEcCtD
Eprosartan—Pain—Methotrexate—esophageal cancer	0.000103	0.00207	CcSEcCtD
Eprosartan—Vomiting—Capecitabine—esophageal cancer	0.000103	0.00207	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—ANXA1—esophageal cancer	0.000102	0.00377	CbGpPWpGaD
Eprosartan—Rash—Capecitabine—esophageal cancer	0.000102	0.00205	CcSEcCtD
Eprosartan—Dermatitis—Capecitabine—esophageal cancer	0.000102	0.00205	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000101	0.00373	CbGpPWpGaD
Eprosartan—Headache—Capecitabine—esophageal cancer	0.000101	0.00204	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—SST—esophageal cancer	9.96e-05	0.00367	CbGpPWpGaD
Eprosartan—Feeling abnormal—Methotrexate—esophageal cancer	9.9e-05	0.00199	CcSEcCtD
Eprosartan—Gastrointestinal pain—Methotrexate—esophageal cancer	9.82e-05	0.00198	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	9.72e-05	0.00358	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—GHRL—esophageal cancer	9.71e-05	0.00358	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	9.67e-05	0.00356	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	9.61e-05	0.00354	CbGpPWpGaD
Eprosartan—Nausea—Capecitabine—esophageal cancer	9.59e-05	0.00193	CcSEcCtD
Eprosartan—Urticaria—Methotrexate—esophageal cancer	9.54e-05	0.00192	CcSEcCtD
Eprosartan—Body temperature increased—Methotrexate—esophageal cancer	9.5e-05	0.00191	CcSEcCtD
Eprosartan—Abdominal pain—Methotrexate—esophageal cancer	9.5e-05	0.00191	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—AQP3—esophageal cancer	9.16e-05	0.00337	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	9.14e-05	0.00336	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	8.99e-05	0.00331	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	8.86e-05	0.00326	CbGpPWpGaD
Eprosartan—Hypersensitivity—Methotrexate—esophageal cancer	8.85e-05	0.00178	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	8.79e-05	0.00324	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	8.79e-05	0.00324	CbGpPWpGaD
Eprosartan—Asthenia—Methotrexate—esophageal cancer	8.62e-05	0.00174	CcSEcCtD
Eprosartan—Pruritus—Methotrexate—esophageal cancer	8.5e-05	0.00171	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	8.36e-05	0.00308	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	8.24e-05	0.00303	CbGpPWpGaD
Eprosartan—Diarrhoea—Methotrexate—esophageal cancer	8.22e-05	0.00166	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—AKAP13—esophageal cancer	8.12e-05	0.00299	CbGpPWpGaD
Eprosartan—Dizziness—Methotrexate—esophageal cancer	7.94e-05	0.0016	CcSEcCtD
Eprosartan—Vomiting—Methotrexate—esophageal cancer	7.64e-05	0.00154	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—KMT2D—esophageal cancer	7.59e-05	0.00279	CbGpPWpGaD
Eprosartan—Rash—Methotrexate—esophageal cancer	7.57e-05	0.00153	CcSEcCtD
Eprosartan—Dermatitis—Methotrexate—esophageal cancer	7.57e-05	0.00152	CcSEcCtD
Eprosartan—Headache—Methotrexate—esophageal cancer	7.53e-05	0.00152	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—PDE4D—esophageal cancer	7.43e-05	0.00274	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKAP13—esophageal cancer	7.38e-05	0.00272	CbGpPWpGaD
Eprosartan—Nausea—Methotrexate—esophageal cancer	7.14e-05	0.00144	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—GNG7—esophageal cancer	7.07e-05	0.0026	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	6.81e-05	0.00251	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ADCYAP1—esophageal cancer	6.76e-05	0.00249	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PDE4D—esophageal cancer	6.75e-05	0.00248	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	6.48e-05	0.00239	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GNG7—esophageal cancer	6.42e-05	0.00236	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	6.4e-05	0.00236	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	6.25e-05	0.0023	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL2—esophageal cancer	6.23e-05	0.00229	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—WWOX—esophageal cancer	6.18e-05	0.00228	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	6.07e-05	0.00224	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—GNG7—esophageal cancer	6.04e-05	0.00223	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FKBP1A—esophageal cancer	5.88e-05	0.00217	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—ANXA1—esophageal cancer	5.79e-05	0.00213	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—WIF1—esophageal cancer	5.75e-05	0.00212	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL2—esophageal cancer	5.65e-05	0.00208	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—SST—esophageal cancer	5.63e-05	0.00207	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—GHRL—esophageal cancer	5.49e-05	0.00202	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CSNK1A1—esophageal cancer	5.31e-05	0.00195	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—ANXA1—esophageal cancer	5.26e-05	0.00194	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	5.16e-05	0.0019	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—SST—esophageal cancer	5.11e-05	0.00188	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	5.09e-05	0.00187	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	5.03e-05	0.00185	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GHRL—esophageal cancer	4.98e-05	0.00183	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	4.98e-05	0.00183	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PFN1—esophageal cancer	4.96e-05	0.00183	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—PIK3CA—esophageal cancer	4.88e-05	0.0018	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	4.85e-05	0.00179	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	4.79e-05	0.00176	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ELMO1—esophageal cancer	4.46e-05	0.00164	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	4.37e-05	0.00161	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKAP13—esophageal cancer	4.36e-05	0.0016	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HIST1H2BM—esophageal cancer	4.02e-05	0.00148	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PDE4D—esophageal cancer	3.99e-05	0.00147	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GNG7—esophageal cancer	3.79e-05	0.0014	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.68e-05	0.00136	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—XIAP—esophageal cancer	3.55e-05	0.00131	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.53e-05	0.0013	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	3.36e-05	0.00124	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CTNNA1—esophageal cancer	3.36e-05	0.00124	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL2—esophageal cancer	3.34e-05	0.00123	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PSME1—esophageal cancer	3.12e-05	0.00115	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PSME2—esophageal cancer	3.12e-05	0.00115	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ANXA1—esophageal cancer	3.1e-05	0.00114	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SST—esophageal cancer	3.02e-05	0.00111	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH3—esophageal cancer	2.94e-05	0.00108	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GHRL—esophageal cancer	2.94e-05	0.00108	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	2.93e-05	0.00108	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FBXW7—esophageal cancer	2.9e-05	0.00107	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH2—esophageal cancer	2.64e-05	0.000972	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC52A3—esophageal cancer	2.61e-05	0.00096	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—BLVRB—esophageal cancer	2.61e-05	0.00096	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.36e-05	0.00087	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFBR2—esophageal cancer	2.34e-05	0.000862	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	2.33e-05	0.000858	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC10A2—esophageal cancer	2.22e-05	0.000817	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CA1—esophageal cancer	2.22e-05	0.000817	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SMAD4—esophageal cancer	2.22e-05	0.000816	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CA2—esophageal cancer	2.03e-05	0.000747	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.98e-05	0.00073	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PLCE1—esophageal cancer	1.89e-05	0.000694	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ADH7—esophageal cancer	1.89e-05	0.000694	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.86e-05	0.000686	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HIF1A—esophageal cancer	1.81e-05	0.000668	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KDR—esophageal cancer	1.73e-05	0.000639	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ADH1B—esophageal cancer	1.65e-05	0.000609	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH1—esophageal cancer	1.63e-05	0.000602	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TYMP—esophageal cancer	1.58e-05	0.000582	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP26A1—esophageal cancer	1.54e-05	0.000566	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALOX15—esophageal cancer	1.5e-05	0.000552	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CREBBP—esophageal cancer	1.48e-05	0.000546	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EGFR—esophageal cancer	1.46e-05	0.000536	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTO1—esophageal cancer	1.43e-05	0.000526	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TPI1—esophageal cancer	1.43e-05	0.000526	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.39e-05	0.000512	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.37e-05	0.000504	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOS3—esophageal cancer	1.33e-05	0.000489	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.32e-05	0.000486	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.31e-05	0.000481	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CA—esophageal cancer	1.26e-05	0.000465	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GNG7—esophageal cancer	1.24e-05	0.000458	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB2—esophageal cancer	1.24e-05	0.000457	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.16e-05	0.000429	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.11e-05	0.000408	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCND1—esophageal cancer	1.1e-05	0.000404	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.1e-05	0.000403	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.09e-05	0.000402	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1A—esophageal cancer	1.06e-05	0.000391	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ENO1—esophageal cancer	1.04e-05	0.000382	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.04e-05	0.000382	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PSME1—esophageal cancer	1.02e-05	0.000377	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PSME2—esophageal cancer	1.02e-05	0.000377	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EP300—esophageal cancer	1.01e-05	0.000372	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.93e-06	0.000329	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP1B1—esophageal cancer	8.83e-06	0.000325	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—esophageal cancer	8.79e-06	0.000324	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGFR—esophageal cancer	8.6e-06	0.000317	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP19A1—esophageal cancer	8.3e-06	0.000306	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HMOX1—esophageal cancer	7.57e-06	0.000279	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CA—esophageal cancer	7.46e-06	0.000275	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.43e-06	0.000274	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCB1—esophageal cancer	7.27e-06	0.000268	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—esophageal cancer	7.22e-06	0.000266	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.5e-06	0.000202	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CREBBP—esophageal cancer	4.86e-06	0.000179	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NOS3—esophageal cancer	4.35e-06	0.00016	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—esophageal cancer	3.98e-06	0.000147	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—EP300—esophageal cancer	3.31e-06	0.000122	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.45e-06	9.01e-05	CbGpPWpGaD
